Cancer stem cells and signaling pathways in radioresistance

Lei Chang, Peter Graham, Jingli Hao, Jie Ni, Junli Deng, Joseph Bucci, David Malouf, David Gillatt, Yong Li*

*Corresponding author for this work

Research output: Contribution to journalArticle

45 Citations (Scopus)
91 Downloads (Pure)

Abstract

Radiation therapy (RT) is one of the most important strategies in cancer treatment. Radioresistance (the failure to RT) results in locoregional recurrence and metastasis. Therefore, it is critically important to investigate the mechanisms leading to cancer radioresistance to overcome this problem and increase patients' survival. Currently, the majority of the radioresistance-associated researches have focused on preclinical studies. Although the exact mechanisms of cancer radioresistance have not been fully uncovered, accumulating evidence supports that cancer stem cells (CSCs) and different signaling pathways play important roles in regulating radiation response and radioresistance. Therefore, targeting CSCs or signaling pathway proteins may hold promise for developing novel combination modalities and overcoming radioresistance. The present review focuses on the key evidence of CSC markers and several important signaling pathways in cancer radioresistance and explores innovative approaches for future radiation treatment.

Original languageEnglish
Pages (from-to)11002-11017
Number of pages16
JournalOncotarget
Volume7
Issue number10
DOIs
Publication statusPublished - 2016

Bibliographical note

Copyright the Author(s) 2015. Version archived for private and non-commercial use with the permission of the author/s and according to publisher conditions. For further rights please contact the publisher.

Fingerprint Dive into the research topics of 'Cancer stem cells and signaling pathways in radioresistance'. Together they form a unique fingerprint.

  • Cite this

    Chang, L., Graham, P., Hao, J., Ni, J., Deng, J., Bucci, J., ... Li, Y. (2016). Cancer stem cells and signaling pathways in radioresistance. Oncotarget, 7(10), 11002-11017. https://doi.org/10.18632/oncotarget.6760